{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:06:48Z","timestamp":1781176008122,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI125160"],"award-info":[{"award-number":["R01AI125160"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A2C2003204"],"award-info":[{"award-number":["NRF-2019R1A2C2003204"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since ID93\/GLA-SE was developed as a targeted BCG-prime booster vaccine, in the present study, we evaluated the protective efficacy of ID93\/GLA-SE as a boost to a BCG-prime against the hypervirulent <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb) K challenge to provide further information on the development and application of this vaccine candidate. Boosting BCG with the ID93\/GLA-SE vaccine significantly reduced bacterial burden at 16 weeks post-challenge while the BCG vaccine alone did not confer significant protection against Mtb K. The pathological analysis of the lung from the challenged mice also showed the remarkably protective boosting effect of ID93\/GLA-SE on BCG-immunised animals. Moreover, qualitative and quantitative analysis of the immune responses following ID93\/GLA-SE-immunisation demonstrated that ID93\/GLA-SE was able to elicit robust and sustained Th1-biased antigen-specific multifunctional CD4<jats:sup>+<\/jats:sup> T-cell responses up to 16 weeks post-challenge as well as a high magnitude of an antigen-specific IgG response. Our findings demonstrate that the ID93\/GLA-SE vaccine candidate given as a BCG-prime boost regimen confers a high level of long-term protection against the hypervirulent Mtb Beijing infection. These findings will provide further and more feasible validation for the potential utility of this vaccine candidate particularly in East-Asian countries, with the predominance of the Beijing genotype, after BCG vaccination.<\/jats:p>","DOI":"10.1038\/s41598-019-52146-0","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:29:48Z","timestamp":1572467388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Long-term protective efficacy with a BCG-prime ID93\/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model"],"prefix":"10.1038","volume":"9","author":[{"given":"Kee Woong","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-5646","authenticated-orcid":false,"given":"Ara","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Nae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1192-6031","authenticated-orcid":false,"given":"Sang-Jun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jae","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"52146_CR1","unstructured":"Global tuberculosis report 2018. Report No. ISBN 978-92-4-156564-6, (World Health Organization, Geneva, 2018)."},{"key":"52146_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes, E. et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med 379, 138\u2013149 (2018).","journal-title":"N Engl J Med"},{"key":"52146_CR3","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren, O. et al. Phase 2b Controlled Trial of M72\/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med 379, 1621\u20131634 (2018).","journal-title":"N Engl J Med"},{"key":"52146_CR4","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1073\/pnas.0712077106","volume":"106","author":"SG Reed","year":"2009","unstructured":"Reed, S. G. et al. Defined tuberculosis vaccine, Mtb72F\/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 106, 2301\u20132306 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"52146_CR5","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1128\/IAI.74.4.2392-2401.2006","volume":"74","author":"L Tsenova","year":"2006","unstructured":"Tsenova, L. et al. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 74, 2392\u20132401 (2006).","journal-title":"Infect Immun"},{"key":"52146_CR6","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1128\/IAI.73.9.5809-5816.2005","volume":"73","author":"SM Irwin","year":"2005","unstructured":"Irwin, S. M. et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 73, 5809\u20135816 (2005).","journal-title":"Infect Immun"},{"key":"52146_CR7","doi-asserted-by":"publisher","first-page":"e80579","DOI":"10.1371\/journal.pone.0080579","volume":"8","author":"T Hoang","year":"2013","unstructured":"Hoang, T. et al. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One 8, e80579 (2013).","journal-title":"PLoS One"},{"key":"52146_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","volume":"28","author":"YA Skeiky","year":"2010","unstructured":"Skeiky, Y. A. et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 28, 1084\u20131093 (2010).","journal-title":"Vaccine"},{"key":"52146_CR9","doi-asserted-by":"publisher","first-page":"e39909","DOI":"10.1371\/journal.pone.0039909","volume":"7","author":"R Billeskov","year":"2012","unstructured":"Billeskov, R., Elvang, T. T., Andersen, P. L. & Dietrich, J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 7, e39909 (2012).","journal-title":"PLoS One"},{"key":"52146_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","volume":"6","author":"A Penn-Nicholson","year":"2018","unstructured":"Penn-Nicholson, A. et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 6, 287\u2013298 (2018).","journal-title":"Lancet Respir Med"},{"key":"52146_CR11","first-page":"824","volume":"5","author":"SJ Kim","year":"2001","unstructured":"Kim, S. J. et al. Transmission of Mycobacterium tuberculosis among high school students in Korea. Int J Tuberc Lung Dis 5, 824\u2013830 (2001).","journal-title":"Int J Tuberc Lung Dis"},{"key":"52146_CR12","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.vaccine.2016.03.029","volume":"34","author":"SB Cha","year":"2016","unstructured":"Cha, S. B. et al. Pulmonary immunity and durable protection induced by the ID93\/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K. Vaccine 34, 2179\u20132187 (2016).","journal-title":"Vaccine"},{"key":"52146_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1128\/CVI.00458-15","volume":"23","author":"SL Baldwin","year":"2016","unstructured":"Baldwin, S. L. et al. Protection and Long-Lived Immunity Induced by the ID93\/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate. Clin Vaccine Immunol 23, 137\u2013147 (2016).","journal-title":"Clin Vaccine Immunol"},{"key":"52146_CR14","doi-asserted-by":"publisher","first-page":"8136","DOI":"10.1073\/pnas.1424063112","volume":"112","author":"T Luo","year":"2015","unstructured":"Luo, T. et al. Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese. Proc Natl Acad Sci USA 112, 8136\u20138141 (2015).","journal-title":"Proc Natl Acad Sci USA"},{"key":"52146_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.3195","volume":"47","author":"M Merker","year":"2015","unstructured":"Merker, M. et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 47, 242\u2013249 (2015).","journal-title":"Nat Genet"},{"key":"52146_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1473-3099(09)70330-5","volume":"10","author":"I Parwati","year":"2010","unstructured":"Parwati, I., van Crevel, R. & van Soolingen, D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 10, 103\u2013111 (2010).","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 3","key":"52146_CR17","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1086\/314072","volume":"31","author":"TF Brewer","year":"2000","unstructured":"Brewer, T. F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31(Suppl 3), S64\u201367 (2000).","journal-title":"Clin Infect Dis"},{"key":"52146_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz, G. A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 271, 698\u2013702 (1994).","journal-title":"Jama"},{"key":"52146_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58, 470\u2013480 (2014).","journal-title":"Clin Infect Dis"},{"key":"52146_CR20","doi-asserted-by":"publisher","first-page":"g4643","DOI":"10.1136\/bmj.g4643","volume":"349","author":"A Roy","year":"2014","unstructured":"Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. Bmj 349, g4643 (2014).","journal-title":"Bmj"},{"key":"52146_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33499-4","volume":"8","author":"E Whittaker","year":"2018","unstructured":"Whittaker, E., Nicol, M. P., Zar, H. J., Tena-Coki, N. G. & Kampmann, B. Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries. Sci Rep 8, 15309 (2018).","journal-title":"Sci Rep"},{"key":"52146_CR22","doi-asserted-by":"crossref","unstructured":"Larsen, S. E. et al. Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment. Vaccines (Basel) 6 (2018).","DOI":"10.3390\/vaccines6020030"},{"key":"52146_CR23","doi-asserted-by":"publisher","first-page":"53ra74","DOI":"10.1126\/scitranslmed.3001094","volume":"2","author":"S Bertholet","year":"2010","unstructured":"Bertholet, S. et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2, 53ra74 (2010).","journal-title":"Sci Transl Med"},{"key":"52146_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/infdis\/jis425","volume":"207","author":"RN Coler","year":"2013","unstructured":"Coler, R. N. et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 207, 1242\u20131252 (2013).","journal-title":"J Infect Dis"},{"key":"52146_CR25","doi-asserted-by":"publisher","first-page":"e0145234","DOI":"10.1371\/journal.pone.0145234","volume":"10","author":"WS Kim","year":"2015","unstructured":"Kim, W. S. et al. Virulence-Dependent Alterations in the Kinetics of Immune Cells during Pulmonary Infection by Mycobacterium tuberculosis. PLoS One 10, e0145234 (2015).","journal-title":"PLoS One"},{"key":"52146_CR26","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1128\/IAI.00019-08","volume":"76","author":"BY Jeon","year":"2008","unstructured":"Jeon, B. Y. et al. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect Immun 76, 5173\u20135180 (2008).","journal-title":"Infect Immun"},{"key":"52146_CR27","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1128\/CVI.05127-11","volume":"18","author":"DJ Ordway","year":"2011","unstructured":"Ordway, D. J. et al. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol 18, 1527\u20131535 (2011).","journal-title":"Clin Vaccine Immunol"},{"key":"52146_CR28","doi-asserted-by":"publisher","first-page":"e1007643","DOI":"10.1371\/journal.ppat.1007643","volume":"15","author":"MJ Rodo","year":"2019","unstructured":"Rodo, M. J. et al. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathog 15, e1007643 (2019).","journal-title":"PLoS Pathog"},{"key":"52146_CR29","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","volume":"172","author":"YA Skeiky","year":"2004","unstructured":"Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172, 7618\u20137628 (2004).","journal-title":"J Immunol"},{"key":"52146_CR30","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","volume":"31","author":"I Leroux-Roels","year":"2013","unstructured":"Leroux-Roels, I. et al. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31, 2196\u20132206 (2013).","journal-title":"Vaccine"},{"key":"52146_CR31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","volume":"35","author":"M Norrby","year":"2017","unstructured":"Norrby, M. et al. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine 35, 1652\u20131661 (2017).","journal-title":"Vaccine"},{"key":"52146_CR32","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","volume":"33","author":"H Geldenhuys","year":"2015","unstructured":"Geldenhuys, H. et al. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine 33, 3592\u20133599 (2015).","journal-title":"Vaccine"},{"key":"52146_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0057-5","volume":"3","author":"RN Coler","year":"2018","unstructured":"Coler, R. N. et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines 3, 34 (2018).","journal-title":"NPJ Vaccines"},{"key":"52146_CR34","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1016\/j.vaccine.2011.02.010","volume":"29","author":"SC Derrick","year":"2011","unstructured":"Derrick, S. C., Yabe, I. M., Yang, A. & Morris, S. L. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29, 2902\u20132909 (2011).","journal-title":"Vaccine"},{"key":"52146_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ni1449","volume":"8","author":"SA Khader","year":"2007","unstructured":"Khader, S. A. et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8, 369\u2013377 (2007).","journal-title":"Nat Immunol"},{"key":"52146_CR36","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1128\/IAI.01392-09","volume":"78","author":"TM Wozniak","year":"2010","unstructured":"Wozniak, T. M., Saunders, B. M., Ryan, A. A. & Britton, W. J. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun 78, 4187\u20134194 (2010).","journal-title":"Infect Immun"},{"key":"52146_CR37","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.4049\/jimmunol.180.3.1962","volume":"180","author":"TJ Scriba","year":"2008","unstructured":"Scriba, T. J. et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 180, 1962\u20131970 (2008).","journal-title":"J Immunol"},{"key":"52146_CR38","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.4049\/jimmunol.0903332","volume":"184","author":"Y Okamoto Yoshida","year":"2010","unstructured":"Okamoto Yoshida, Y. et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184, 4414\u20134422 (2010).","journal-title":"J Immunol"},{"key":"52146_CR39","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.4049\/jimmunol.1101377","volume":"187","author":"SA Khader","year":"2011","unstructured":"Khader, S. A. et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 187, 5402\u20135407 (2011).","journal-title":"J Immunol"},{"key":"52146_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/imm.12130","volume":"140","author":"D Freches","year":"2013","unstructured":"Freches, D. et al. Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 140, 220\u2013231 (2013).","journal-title":"Immunology"},{"key":"52146_CR41","doi-asserted-by":"publisher","first-page":"e1004099","DOI":"10.1371\/journal.ppat.1004099","volume":"10","author":"R Gopal","year":"2014","unstructured":"Gopal, R. et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 10, e1004099 (2014).","journal-title":"PLoS Pathog"},{"key":"52146_CR42","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/infdis\/jir592","volume":"204","author":"C Desel","year":"2011","unstructured":"Desel, C. et al. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204, 1573\u20131584 (2011).","journal-title":"J Infect Dis"},{"key":"52146_CR43","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1016\/j.vaccine.2015.10.115","volume":"33","author":"MT Orr","year":"2015","unstructured":"Orr, M. T. et al. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. Vaccine 33, 6570\u20136578 (2015).","journal-title":"Vaccine"},{"key":"52146_CR44","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","volume":"188","author":"SL Baldwin","year":"2012","unstructured":"Baldwin, S. L. et al. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 188, 2189\u20132197 (2012).","journal-title":"J Immunol"},{"key":"52146_CR45","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.4049\/jimmunol.178.6.3721","volume":"178","author":"J Dietrich","year":"2007","unstructured":"Dietrich, J., Billeskov, R., Doherty, T. M. & Andersen, P. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol 178, 3721\u20133730 (2007).","journal-title":"J Immunol"},{"key":"52146_CR46","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.micinf.2009.07.005","volume":"11","author":"C Rouanet","year":"2009","unstructured":"Rouanet, C., Debrie, A. S., Lecher, S. & Locht, C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 11, 995\u20131001 (2009).","journal-title":"Microbes Infect"},{"key":"52146_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep44151","volume":"7","author":"KW Kwon","year":"2017","unstructured":"Kwon, K. W. et al. Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Sci Rep 7, 44151 (2017).","journal-title":"Sci Rep"},{"key":"52146_CR48","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1096\/fj.201802604R","volume":"33","author":"KW Kwon","year":"2019","unstructured":"Kwon, K. W. et al. Vaccine efficacy of a Mycobacterium tuberculosis Beijing-specific proline-glutamic acid (PE) antigen against highly virulent outbreak isolates. Faseb j 33, 6483\u20136496 (2019).","journal-title":"Faseb j"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52146-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52146-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:10:49Z","timestamp":1671289849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52146-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52146"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52146-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"14 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Reed is a founder of, and holds an equity interest in, Immune Design Corp., a licensee of certain rights associated with GLA. Dr. Kwon, Dr. Lee, Dr. Larsen, Dr. Baldwin, Dr. Coler, Dr. Cho, Dr. Ha, and Dr. Shin declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15560"}}